AAPS FAVORS DEVELOPING RELATIONS WITH APhA/APS
AAPS FAVORS DEVELOPING RELATIONS WITH APhA/APS, according to an Aug. 6 letter from American Association of Pharmaceutical Scientists' (AAPS) President Leslie Benet to members of the new association. Referring to his group's troublesome split from the American Pharmaceutical Association/Academy of Pharmaceutical Sciences (APhA/APS), Benet maintained: "What appeared to be a divisive struggle only six months ago is probably no longer a struggle and may prove, in the end, to better serve both the scientific needs of the scientists and the professional needs of the pharmacists." Benet and pharmaceutical research colleagues separated from their APhA/APS affiliation last March in what was reported as an APhA "schism." Benet declared that the "one overriding reason" for forming an independent society of pharmaceutical scientists was "the fact that [APhA] President Schlegel and the Board of Trustees have adopted the philosophy that APhA must operate as a single strategy center." President of APS at the time, Benet urged a federated approach that would give APS a greater voice within the APhA organization. In his August letter, Benet reported that one of the three difficulties "that could prevent the development of excellent cordial relations between APhA and AAPS . . . has been resolved." Benet was referring to APhA's invitation that AAPS cosponsor the JUC Pharm Sci meeting between U.S. and Japanese pharmaceutical scientists, to be held in Hawaii in December, 1987. Furthermore, Benet predicted that the other two issues, "the quarter of a million dollar reserve in the APS treasury which pharmaceutical scientists had raised over the years" and "the endowed scientific awards such as the Higuchi Research Prize and the Kolthoff Gold Medal for which funds were raised exclusively by the efforts of pharmaceutical scientists" would also be resolved with time. "As the scientific scope and goals of APhA and AAPS become better defined," Benet suggested that "a moral legacy (as opposed to a legal right) will develop with respect to the funds involved."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth